1-3 of 3
Ulrich von Gruenhagen, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Bendamustine Plus Rituximab Is Superior in Respect of Progression Free Survival and CR Rate When Compared to CHOP Plus Rituximab as First-Line Treatment of Patients with Advanced Follicular, Indolent, and Mantle Cell Lymphomas: Final Results of a Randomized Phase III Study of the StiL (Study Group Indolent Lymphomas, Germany).

Mathias J Rummel, MD, PhD, Norbert Niederle, Georg Maschmeyer, Andre Banat, MD, MBA, Ulrich von Gruenhagen, MD, Christoph Losem, Gerhard Heil, Manfred Welslau, Christina Balser, Ulrich Kaiser, Harald Ballo, Eckhart Weidmann, Heinz A Duerk, Dorothea Kofahl-Krause, Fritz Roller, Juergen Barth, Dieter Hoelzer, MD, PhD, Axel Hinke, Wolfram Brugger
Journal: Blood
Blood (2009) 114 (22): 405.
https://doi.org/10.1182/blood.V114.22.405.405
Published: 2009
Journal Articles

First-Line Treatment with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Improves Overall Survival (OS) in Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Randomized Phase III Trial On Behalf of An International Group of Investigators and the German CLL Study Group.

Michael Hallek, MD, Guenter Fingerle-Rowson, MD, PhD, Anna-Maria Fink, MD, Raymonde Busch, Jiri Mayer, MD, Manfred Hensel, MD, Georg Hopfinger, MD, Georg Hess, MD, Ulrich von Gruenhagen, MD, Manuela A. Bergmann, MD, John Catalano, MD, Pier Luigi Zinzano, MD, Federico Caligaris Cappio, MD, John F Seymour, MD, PhD, Alain Berrebi, MD, Ulrich Jaeger, MD, Bruno Cazin, MD, Marek Trneny, MD, Anne Westermann, Clemens-Martin Wendtner, MD, Barbara F. Eichhorst, MD, Peter Staib, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Myriam Mendila, MD, Michael Kneba, MD, PhD, Hartmut Doehner, MD, Stephan Stilgenbauer, MD, Kirsten Fischer, MD
Journal: Blood
Blood (2009) 114 (22): 535.
https://doi.org/10.1182/blood.V114.22.535.535
Published: 2009
Journal Articles

Immunochemotherapy with Fludarabine (F), Cyclophosphamide (C), and Rituximab (R) (FCR) Versus Fludarabine and Cyclophosphamide (FC) Improves Response Rates and Progression-Free Survival (PFS) of Previously Untreated Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL)

Michael Hallek, MD, Guenter Fingerle-Rowson, MD, PhD, Anna- Maria Fink, MD, Raymonde Busch, Jiri Mayer, MD, Manfred Hensel, MD, Georg Hopfinger, MD, Georg Hess, MD, Ulrich von Gruenhagen, MD, Manuela A. Bergmann, MD, John Catalano, MD, Pier Luigi Zinzani, MD, Federico Caligaris Cappio, MD, John Francis Seymour, MBBS, Alain Berrebi, MD, Ulrich Jaeger, MD, Bruno Cazin, MD, Marek Trneny, MD, PhD, Anne Westermann, Clemens-Martin Wendtner, MD, Barbara F. Eichhorst, MD, Peter Staib, MD, Sebastian Boettcher, MD, Matthias Ritgen, MD, Stephan Stilgenbauer, MD, Myriam Mendila, MD, Michael Kneba, MD, PhD, Hartmut DoĢˆhner, MD, Kirsten Fischer, MD
Journal: Blood
Blood (2008) 112 (11): 325.
https://doi.org/10.1182/blood.V112.11.325.325
Published: 2008